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Immunization of human beings against typhoid fever has been practiced for 
more than 60 years, probably having been first performed by Wright in  1897 
(1). Large scale active immunization was first employed in the British Armies 
in  South  Africa during  the  Boer War,  with  controversial  results  (2).  Later, 
more systematic trials were carried out, mainly in India (3). 
As a consequence  of the fairly successful experiences  of the British in immunizing 
their troops, antityphoid vaccination was initiated on a voluntary basis in the United 
States Army in 1908 by Major F. F. Russell of the Army Medical Corps (4). Compul- 
sory vaccination for all Army recruits was made effective in 1911, and by the end of 
that year, 85 per cent of all Army persound had been immunized (5). Within the next 
few years, antityphoid vaccination was made obligatory for  all  military  services. 
Meanwhile, the extensive British experience in India, which provided an opportunity 
for comparing typhoid rates in unvaccinated versus vaccinated volunteers, was very 
carefully examined by Greenwood  and Yule (6), who concluded  that the efficacy of 
typhoid immunization had been dearly established.  Subsequent  reports of various 
investigators  generally have  indicated  that  antityphoid  vaccination has  been  an 
effective,  if not the dominant, factor in lowering the incidence  and case fatality rates 
of typhoid fever in military organizations. 
On the other hand, these studies have been criticized  on the ground that few, if any 
of them, were adequately controlled.  In most instances, controls were simply those in- 
dividuals who happened not to be vaccinated, without regard to any differences  in 
degree of exposure between the two groups. Thus, on the basis of available data, some 
epidemiologists  (e.g., Cockburn, 2), while not denying the apparent protection afforded 
by typhoid vaccine, have questioned the validity of the conclusions cited above. This 
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doubt was increased further by a number of reports during the past two decades  on 
the occurrence of unexpected numbers of cases of typhoid fever in vaccinated groups. 
Limited outbreaks of this disease in American soldiers  in the Mediterranean (7) and 
Pacific (8) areas during World War II have been described, and extensive outbreaks 
have been reported among vaccinated British soldiers  in the Middle East (9-11) and 
elsewhere  (12).  Indeed, the findings of Marmion et al.  (11) led to some uncertainty 
regarding the degree of immunity induced by the disease itself. 
Consequently, a critical re-evaluation of antityphoid immunization  was undertaken 
several years ago at this institution. Since it was impractical at that time to carry out 
definitive studies on this problem in man, a suitable experimental animal was sought. 
Laboratory testing of typhoid vaccines has been performed customarily in mice, 
and, although it is possible to  distinguish between different types and batches of 
vaccines by  the  mouse protection  test,  a  direct  correlation between  the  mouse  - 
protective potency of a vaccine and its ability to protect man against infection with 
the typhoid bacillus has not yet been established. Hence, it was felt that more perti- 
nent information on typhoid prophylaxis might be obtained ff a species closely related 
to man were  employed. Accordingly, the chimpanzee was selected as the animal of 
choice  for re-evaluating the effectiveness  of antityphoid immunizing agents. It was 
first necessary to define the conditions under which this disease  could be established 
consistently in the chimpanzee. An account of these studies is given in the first com- 
munication in this series  (13). The earlier results of Grfinhaum (14) and Metchnikoff 
and Besredka  (15,  16)  were  confirmed and extended; it was  demonstrated that a 
disease  with  clinical, laboratory, and histopathological findings closely  resembling 
those occurring in human typhoid infections could be produced in chimpanzees. In a 
subsequent report (17),  it was shown that recovery from this disease conferred im- 
munity to a second challenge. 
The next phase of these studies, described in the present report, deals with 
the capability of immunizing  agents to protect chimpanzees against this experi- 
mental infection. 
Materials  and  Methods 
Experimental Animals.--During  the course of this investigation, which extended over a 
period of 3 years, a total of sixty-seven young chimpanzees of both sexes ranging in weight from 
14 to 35 pounds were used. These animals were obtained from the Congo and West Africa, and 
were housed and maintained  at this institution  for at least 2 months prior to this study. Several 
stool cultures from each animal were examined to ascertain that they were free of Group D 
Salmonellae. 
Challenge Organisms.--Salmonella  typhosa strain Ty2,  phage-type  El,  and strain 2593, 
phage-type T, were utilized as challenge cultures. The characteristics of these strains and their 
infectivity for chimpanzees are given in a previous publication (13). 
Challenge Procedures.--The  preparation  of the challenge suspensions and the method of 
challenge were the same as those employed previously (13). A 5 hour veal infusion agar culture 
of either Ty2 or 2593 was harvested in saline and the chimpanzees challenged orally by feeding 
each a banana inoculated with the desired number of organisms. The number of viable bacilli 
contained in the dose administered was determined tubidimetrically and checked by subse- 
quent viable count. The mouse virulence of each challenge culture was ascertained by intra- GAINES ET AL.  329 
peritoneal inoculation, employing saline suspensions of the organisms. LDs0 values of approxi- 
mately 3 X  106 bacilli, as calculated by the method of Reed and Muench (18) were obtained. 
The presence of Vi and O antigens in the challenge inocula and the O-inagglutinability of these 
challenges were confirmed by serological tests with rabbit  antisera  produced  as previously 
described (17). 
Bacteriological Pracedurvs.--Stoo]  specimens were cultured regularly on duplicate SS agar 
plates and occasionally in selenite-F enrichment broth, on MacConkey agar and Wilson-Blair 
bismuth sulfite agar. Lactose-negative colonies were transferred to Kligler's iron agar slants 
to ascertain biochemical changes characteristic of S. typhosa.  From time to time, confirmatory 
checks of these cultures were made by more extensive biochemical procedures and by serologi- 
cal methods. Blood was cultured by inoculating 2 to 4 ml into 40 ml of trypticase soy broth 
containing 0.1 per cent agar and 0.1 per cent sodium citrate. When bacterial growth was evi- 
dent, or after 7 days of incubation in the absence of discernible growth, subcultures were made 
to SS agar. Colonies suspected of being S. typkosa were handled in the same manner as stool 
culture isolates. Blood cultures were considered negative if growth of S. typhosa failed to occur 
within 7 days. 
Clinical and Laboratory Observation of Challenged Animals.--For the duration of the experi- 
ment after challenge (generally 28 days), the course of infection was followed by daily bac- 
teriological  examination  of  stools,  blood  cultures,  either  daily  or  every other  day,  close 
observation for alterations in appetite, appearance or behavior, and periodic examination of 
serum for the presence and titer of O, H, and Vi antibodies. Rectal temperatures were taken 
dally, and an animal was considered to be febrile when its temperature was greater than 1.5°F 
above its mean prechallenge normal temperature. 
Serological Examinations.--Serum  titers of antibody to the flagellar and  somatic compo- 
nents of S. typhosa were determined by the usual bacterial agglutination procedures employed 
by the Department of the Army (19), while Vi antibody was measured by the hemaggiutina- 
tion technique of Landy and Lamb (20). 
Immunizing Products.--A monovalent acetone-killed and dried typhoid vaccine (AK) was 
prepared from the Ty2 strain of S. typhosa.  This vaccine was made according to the method 
described by Landy (21) except for the omission of the paratyphoid components. On reconsti- 
tution to 50 ml with distilled water, each 0.5 ml dose contained approximately 500  X  10' 
organisms. The heat-killed, phenol-preserved vaccine (HP) employed was the standard  fluid 
typhoid and paratyphoid vaccine used as routine by the Armed Services. The product utilized 
in these studies was Lot 5802-6211272,  prepared by Eli Lilly Company, Indianapolis. Each 
0.5  ml dose contained 500  X  10' S.  typhosa  58,  125  X  106 S. paratyphi, and  125  X  106 S. 
schottmuelleri.  Both vaccines met or exceeded the potency requirements of the National In- 
stitutes of Health  (22),  which are based  on mucin suspension  of the challenge cultures.  In 
mouse protection tests employing saline challenges,  it was observed by one of us  (SG)  that 
AK vaccines prepared from S. typhosa  Ty2 were approximately 30 to 70 times more potent 
than typical HP typhoid-paratyphoid  vaccines. Comparable results in experiments utilizing 
both types of challenge have been reported for similar vaccines by Edsall et al. (23). 
In addition to the aforementioned vaccines, purified Vi and O antigens were used as im- 
munizing agents. The Vi antigen utilized was the highly polymerized, acidic polysaccharide 
consisting of repeating  units  of N-acetyl-D-galactosaminuronic acid (24--26) and  had  been 
isolated from a  Vi strain of Esckerictda  coli  (27).  The purified O antigen,  derived from S. 
typhosa 0-901 (28), was a phosphorylated lipopolysaccharide. 
RESULTS 
The issues explored in the present  study were:  (a)  whether  typhoid vaccine 
would confer protection against  the experimental disease, (b)  comparison  of the 330  INFECTION  AND  IMMUNITY IN  TYPHOID  FEVER.  III 
effectiveness in  chimpanzees  of  typhoid vaccines  of  different immunogenic 
potency in mice, and (c) the capacity of the purified Vi and 0  antigens, either 
singly or in combination, to induce immunity to infection• 
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FIG. I.  Antibody responses of chimpanzees to AK vaccine 
Antibody Responses Following Immunization.-- 
A total of 23 chimpanzees were immunized with AK vaccine by subcutaneous inoculation 
with three 0.5 ml doses at 14 day intervals, followed by a 0.5 ml booster injection via the same 
route 2 months later. The geometric mean antibody responses  of this group of animals are given 
in Fig. 1. Ten additional chimpanzees, inoculated by the same schedule, were immunized with 
HP vaccine, and produced the mean antibody levels shown in Fig. 2. 
As seen in these figures, both vaccines stimulated the production of good O 
and H  antibody levels. The O responses to the 2 products were essentially the 
same, but greater H antibody titers were attained following the administration 
of the AK vaccine. In contrast to the O and H responses, however, Vi antibody GAx~ms ~x As.  331 
titers were low in both instances.  These findings in the chimpanzee  are essen- 
tially comparable to those observed in man under similar immunizing regimens. 
With  respect  to  the  isolated  antigens,  4  chimpanzees  were  injected  with 
purified Vi antigen,  4 with purified O antigen,  and 4 with both Vi and O. All 
animals received  4 subcutaneous  injections,  each consisting  of 40 micrograms 
of antigen,  at intervals indicated  in Fig. 3. The levels of antibody produced by 
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Fzo. 2.  Antibody responses of chimpanzees to HP vaccine 
these animals resembled those seen in chimpanzees following immunization  with 
whole organism vaccines;  i.e., 0  antibody levels were good, but Vi responses 
were low. In man, on the other hand, Landy et al. (29) showed that immuniza- 
tion with isolated antigens resulted in satisfactory levels of Vi as well as O 
antibody. 
Protection Provided by AK Vaccine.-- 
Ten chimpanzees were inoculated with AK vaccine, and 2 weeks after the booster inocula- 
tions these animals together with 7 unvaccinated control chimpanzees were challenged orally 
with 5 billion viable Ty2 bacilli. The responses of these animals are given in Table I. 332  INFECTION  AND  TM~UNITY  IN  TYPHOID  FE~-ER,  III 
Bacteriemia  could  be  demonstrated  in  5  of  the  7  unvaccinated  control 
chimpanzees, the first positive cultures appearing 4  to 8 days after challenge. 
The number of positive blood cultures per animal varied from one to six and 
the periods of bacteriemia ranged from 1 to 10 days.  In contrast, none of the 
10 immunized chimpanzees showed any evidence of bacteriemia at any time. 
Positive stool cultures were obtained from all but one of the animals within 
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FIG. 3. Antibody responses of chimpanzees  to purified Vi and O antigens 
24 hours following challenge, a  finding indicating that  the animals had been 
exposed to viable typhoid bacilli throughout the gastrointestinal tract.  Mter 
the 2nd day and until the 5th day, S. typhosa could not be isolated from the 
stools of any of the chimpanzees. Differentiation between the two groups ap- 
peared from the 5th postchallenge day, on; 5 of the  7 controls exhibited 1 or 
more positive stools during the remainder of the experiment. (Of the 5 animals 
showing  bacteriemia,  4  had  positive  stool  cultures;  the  other  stool-positive 
animal was one of the 2 in which bacteriemia was not demonstrated.) In con- 
trast, only 2 of the 10 vaccinated controls were positive. It is of interest that 1 
of the  2  stool-positive immunized  animals  became a  temporary carrier and G~m~-~s ET hL.  333 
continued to shed typhoid bacilli in his stool intermittently for 90 days after 
challenge (Chimpanzee Jet referred to in Paper I  (13)). 
Pyrexia of varying degree and duration was noted in the same 5 unvaccinated 
chimpanzees in which bacteriemia was evident. On the other hand, of the 10 
vaccinated animals, only one showed a short febrile period (3 days), with a peak 
of  1.8°F  above its  average prechallenge  temperature.  Lethargy was  clearly 
evident in 4 of the control chimpanzees, and 3 of these 4 also were anorectic. 
In contrast, all of the immunized group remained lively and continued to eat 
well. Weight losses of approximately 9 and 11 per cent were observed in 2 of 
the control animals which had been markedly anorectic for 10 and  14 days, 
respectively. The weights of all other chimpanzees in either group remained 
essentially the same during the 4 weeks following challenge. 
Examination of sera obtained at approximately weekly intervals after chal- 
TABLE I 
Response of AK-Vaccinated and Unvaccinated Chimpanzees to Oral Challenge with 5 X  10  9 
S. typkosa Tyg 
Group 
Immunized ......... 
Unimmunized  ....... 
Animals showin~ 
I 
No. of  Bscterlemla  ]  Fever  Antibody  rises 
animals  .....  [ 
No. of  [  No. of  ]  No. of  No. of  ...  ^ 
animals  days  [  animals  days  vl  u  H 
I 
lo  o  I  o  i  i  ]  3  io  o  o 
7  5  [  5  [32  15t717 
lenge revealed that all 7 control chimpanzees, in which prechallenge typhoid 
antibodies were absent, showed development of O and H  agglutinins, while the 
5  with  bacteriemia produced  Vi  antibody  as  well.  The positive  serological 
findings on the 2 apparently healthy controls provided evidence for subclinical 
infection in these animals, since it had been shown (13) that antibody response 
to ingested typhoid bacilli occurred only if living organisms were fed. In the 
vaccinated chimpanzees, neither the moderately high O and H  antibody levels 
nor the low Vi titers resulting from immunization increased following challenge, 
but on the contrary, tapered off. 
Comparison of the Immune Status at 2 and 14 Weeks Following  Vaccination.-- 
The results presented in Table I show that monovalent AK vaccine was highly 
protective  when  the  animals  were  challenged  2  weeks  following  a  booster 
inoculation, a time at which the immune state was presumed to be maximal. 
To ascertain the effectiveness  of this vaccine for a longer interval between immunization 
and challenge, the responses of chimpanzees challenged 3~,~ months (14 weeks) following 
booster inoculations were compared with those observed in animals challenged at 2 weeks. At 334  IN'FECTION  AND  IMMUNITY  IN  TYPHOID  FEVER.  III 
the same time a  group of chimpanzees immunized with the standard HP vaccine were chal- 
lenged 2 weeks after a  booster inoculation with this product. The responses of these animals 
as well as an unimmunized group to challenge with 3 billion viable Ty2 bacilli are illustrated in 
Table II. 
Bacteriemia was demonstrated in 4  out of 5 of the unvaccinated controls 
(group IV), the first positive cultures appearing from the 4th to the 6th day 
after challenge. The number of positive blood cultures per animal varied from 
2 to 7, and the total period of bacteriemia for this group was 21 days (an average 
of 4.2 days per animal). On the other hand, bacteriemia of short duration (1 
and 2 days) was seen in 2 of the 4 chimpanzees in group I  (AK, 14 week), and 
1 day of bacteriemia occurred in 1 animal in group III (HP, 2 week). 
Fever of varying degree and duration was observed in 4  of the 5 control 
TABLE  II 
Response  of AK- and  HP-Vaccinated  Chim 
4 
5 
5 
I 
No. Of 
animals  Group  Immunized with 
I  AK vaccine 
II  AK vaccine 
III  HP vaccine 
IV  Unimmunized 
Wks. 
booster to 
challenge 
i 
14 
2 
2 
)anzees to Ingestion  of 3  X  10 ° S.  typkosa  Ty2 
Animals showing 
Bacterlemia  Fever  Antibody rises 
NO.  of 
animals 
No. of  NO.daysOf animals 
3  ~  2 
o13 
1  2 
21  4 
No. of 
days 
t  6 
i  3 
i  22 
Vi  [  O  H 
--.j .--  -- 
1013  2 
o  o  o 
0  0  1 
l!s  s 
chimpanzees. In the immunized animals, 2 of the 4 in group I, 3 of the 4 in 
group II, and 2 of the 5 in group III exhibited febrile responses.  However, 
there were 22 days of fever in the control group (4.4 days per animal) in con- 
trast to only 6, 4, and 3 days of fever (averages of 1.5, 1, and 0.6 per animal), 
respectively, in groups I, II, and III. 
Little difference was apparent between the control animals and any of the 
vaccinated groups as regards the number of positive stool cultures. The usual 
early positive isolates were obtained from 14 of the 18 animals in this experi- 
ment during the first few days following challenge, but after the 3rd day, all 
stools were negative for S. typhosa except for a single positive in one animal of 
group II and 3 positives in one control chimpanzee. 
Tests on serum specimens obtained 10, 19, and 28 days following challenge 
showed development of O  and H  agglutinins in all 5 of the control animals, 
but only 1 of them produced detectable Vi antibody. In the group of 4 animals 
challenged  14  weeks  after  booster  inoculation with  AK  vaccine  (group  I), 
slight to moderate increases in O and H  agglutinin titers above thnse seen at GAINES  ET  AL.  335 
the time of challenge occurred in 3 and 2 animals, respectively. Vi antibody was 
not apparent immediately prior to challenge and could not be demonstrated 
during the postchallenge  period.  All of the animals challenged  2 weeks fol- 
lowing booster inoculations  (groups II and III) exhibited moderate to high O 
and H  agglutinin titers at the time of challenge,  irrespective  of the type of 
vaccine employed. Prechallenge Vi antibody was evident in 2 of the 4 group II 
chimpanzees and in 1 of the 5 group III animals. Following challenge, antibody 
titers in these 2 groups  either remained the same  or declined,  except  for a 
slightly increased H  agglutinin titer in one group III animal. 
Protection  Afforded  by  Vaccines  against  Challenge  with  a  "Wild"  Strain  of 
s.  TrPRosa.--It  is  evident that under the test conditions  employed in this 
study, AK or H_P vaccines  effectively immunized chimpanzees  against chal- 
lenge with the stable, mouse virulent Ty2 strain of S. typhosa.  Since this strain 
TABLE III 
Response o.1"  AK- and HP-Vaccinat~ Chim ~anzees to Oral Challenge with 100 X  I09 S. typhosa 
2593  "W//,d"  Strain) 
Immunized with  No. of 
animals 
~_K vaccine. 
~IP vaccine. 
Unimmunized. 
Vc~k$, 
booster to 
challenge 
2 
2 
Animals showing 
Baeterlemla  Fever  Antibody  rises 
No. of  No. of 
animals  days 
2  6 
1  1 
5  20 
No. of  No. of 
animals  days 
1  2 
0  0 
1  8 
Vi  O  H 
0  1  4 
0  0  3 
2  5  5 
had been carried  in the laboratory for several  decades,  it was important to 
determine whether the typhoid vaccines  under study would protect against 
challenge with a more recently isolated typhoid culture. 
Accordingly, groups of chimpanzees  were immunized with these vaccines in the usual man- 
net, and challenged orally 2 weeks later with 100 billion viable S. typhosa 2593, a strain which 
had been isolated recently from a carrier responsible for a case of typhoid fever. It should be 
pointed out that although strain 2593 was a freshly isolated culture virulent for mice, the dis- 
ease it produced in unimmunized chimpanzees was somewhat milder than that resulting from 
a Ty2 challenge; i.e., there occurred fewer instances of fever, lethargy, and anorexia. 
The results of this experiment,  summarized  in Table III, show that both 
vaccines afforded protection to chimpanzees fed the "wild" strain of S. typhosa. 
The AK vaccine  in this experiment  appeared to be  somewhat  less effective 
than the HP product, but this difference may not be significant. In any case, 
the number of positive blood  cultures and the duration of bacteriemia was 
markedly reduced in the vaccinated chimpanzees,  and moreover,  bacteriemia 336  INFECTION  AND  IM~fUNITY  IN  TYPHOID  FEVER.  III 
appeared later than in the controls.  Febrile  response was observed in only 2 
of the 15 animals in this experiment,  but positive stool cultures were obtained 
on 13 occasions in 4 of the 5 control  chimpanzees, in contrast to only 4 posi- 
tives in 3 of the 10 vaccinated animals. Typical O and H agglufinin develop- 
ment occurred in all of the controls,  and 2 of these animals exhibited  low Vi 
antibody titers in response to challenge. In the immunized  chimpanzees,  the 
high prechallenge  O and H  antibody titers remained  unchanged,  declined, or 
increased  slightly (one 2-fold dilution). Vi antibody could not be detected in 
any of the vaccinated animals immediately prior to or following challenge. 
Immunization  with Isolated  Typhoid Antigens.--An  area  of major concern 
in this laboratory has been the characterization of the Vi and O antigens of 
S.  typhosa  with a  view  toward their ultimate use  as  a  replacement  for the 
bacterial vaccine, provided their ability to protect against typhoid fever could 
be demonstrated. Studies on the immunogenic properties  of these antigens in 
mice had been  reported by several  investigators (30-33). Landy and his co- 
workers  (32, 34,  35)  showed that Vi was highly effective in protecting these 
animals  against intraperitoneal or intracerebral challenge with fully virulent 
typhoid bacilli, whereas  the O antigen was relatively ineffective. In view of 
these  results  in mice  and the observations  that isolated  Vi  and O antigens 
stimulated excellent antibody production in man (29), these components were 
examined  for their effectiveness in protecting chimpanzees  challenged  orally 
with S. typhosa. 
Groups of animals were given 3 weekly injections of 40 micrograms each of either Vi (Group 
V), O (Group O), or both (Group V-O), followed by a booster inoculation 2 weeks thereafter. 
All injections were made subcutaneously, employing 0.5 ml volumes. A fourth group of unin- 
oculated chimpanzees served as controls. One month subsequent to the booster injections the 
animals were challenged with 3 billion viable Ty2 bacilli; their responses are presented in Ta- 
ble IV. 
Typhoid bacilli were cultured from the blood of all except one control  and 
2  Vi-immunized  chimpanzees.  However,  the  duration of bacteriemia  in the 
O-immunized and control chimpanzees was approximately 2 to 3 times longer 
than that seen in the animals previously inoculated with Vi antigen alone or 
with Vi plus O. The proportion  of chimpanzees exhibiting  a febrile response 
was high in all  groups  except  the Vi-immunized animals,  only one of which 
became  febrile.  Furthermore, the duration of fever  in this latter group  was 
only one-fourth  that of the controls,  while the length  of febrile periods  seen 
in the animals of groups O and V-O was  intermediate. Positive  stool isolates 
were obtained irregularly from all groups from the 2nd  day on; however, the 
8 animals receiving Vi antigen yielded a total of 8 positive isolates, whereas 32 
positive  specimens were cultured from the other 9 animals in the experiment. 
All  5  control  chimpanzees,  including  the  asymptomatic animal,  free  of 
typhoid antibodies at the time of challenge, produced good O agglutinin levels. GAINES  ET  AL.  337 
Two developed moderately high Vi antibody titers. Six of the 8 animals given 
O antigen developed O agglutinin titers greater than the levels present at the 
time of challenge,  while  all  of the chimpanzees in group V  (O-negative pre~ 
challenge)  formed O antibody. With regard to Vi antibody, 3 group O animals, 
all 4 of which were negative prior to challenge, produced measurable Vi hemag- 
glutinin levels.  Only 1 of group V and 2 of group V-O chimpanzees exhibited 
Vi  antibody immediately prior  to challenge,  and  their  Vi levels did not in- 
crease as a  result  of infection.  The  remaining  animals  of these two groups, 
which were negative for Vi antibody at the time of challenge, remained negative 
subsequent to challenge.  H antibody levels were not determined in this experi- 
ment. 
TABLE  IV 
Protection Afforded Chimpanzees by Purified  Vi and 0  Antigens against Oral Challenge wlth 
3 X  lOg S. typhosa Ty2 
Group 
V 
0 
V-O 
Unimmunized 
! Immunized 
with 
i 
Vi antigen 
O  antigen 
Vi and O 
antigens 
I 
Wks° 
booster to 
chsUenge 
Animals showing 
Bacteriemla  Fever  Antibody ris~ 
No. of 
animals 
No. of 
days 
6 
17 
9 
17 
No. of  No. of 
animals  days 
1  8 
3  19 
3  24 
4  32 
Vl  o 
0  4 
3  4 
0  2 
2  5 
DISCUSSION 
It is evident from the results of this study that  typhoid vaccines afforded 
chimpanzees  significant  protection  against  challenge  capable  of  inducing 
disease  in  non-immunized  anlmals.  Two  types  of  whole  bacterial  vaccines 
provided excellent protection against infection with homologous or heterologous 
strains. The monovalent acetone-killed and dried vaccine prepared from strain 
Ty2 produced in 10 chimpanzees a solid immunity against challenge with this 
strain.  In contrast,  5 of 7 control animals manifested laboratory and clinical 
evidence of disease,  while  the remaining  2  showed inapparent  infection.  In 
another  experiment,  average periods of approximately 5 days of bacteriemia 
and fever were observed in 4 of the 5 unimmunized chimpanzees infected with 
this strain; in contrast, none of the 4 vaccinated animals exhibited bacteriemia, 
and the average duration of fever was only slightly over 1 day. When a "wild" 
heterologous strain was employed as challenge,  3 of 5 immunized chimpanzees 
were  completely asymptomatic,  and  the  infection  iu  the  remaining  2  was 338  INFECTION"  AND  IMMUNITY  IN"  TYPHOID  FEVER.  III 
definitely mitigated. All 5 controls exhibited  frank infection, although febrile 
response to this strain was minimal. 
Heat-killed,  phenol-preserved  vaccine  also  was  highly  effective  against 
challenge with either Ty2 or the "wild" strain. Only 3 days of fever occurred 
in the 10 animals given this type of vaccine, and only 2 positive blood cultures 
were obtained. 
In the animals challenged after a 14-week interval following immunization, 
2 of the 4 vaccinated animals exhibited 6 days of fever and 3 days of bacteriemia. 
Although the protection afforded  this group  was less than that seen in the 
animals  challenged  2 weeks following the same  immunizing  regimen,  it was 
nevertheless  considerable  when compared  with the findings in the 5 control 
chimpanzees.  Thus,  the results  of this limited experiment  suggest  that the 
immunity conferred by typhoid vaccine  extends  for at least several months, 
and hence cannot be regarded  simply as a transient non-specific enhancement 
of resistance or as an interference effect. 
The suggestion has been made that strains of bacilli freshly isolated from 
active cases be utilized in the preparation of typhoid vaccines. It is of interest 
in this regard that, in the present study, vaccines prepared from laboratory 
strains of the typhoid bacillus  stimulated resistance  not only against homol- 
ogous challenge but against heterologous challenge as well. The Ty2  vaccine 
was effective against a  homologous and a  heterologous  strain, while the HP 
vaccine,  prepared  from  S.  typhosa 58,  immunized against  2  heterologous 
strains.  The 3 strains involved  (Ty2,  58,  and 2593) differ in origin,  date of 
isolation, history of handling, and in phage type (13, 36-38). However, despite 
quantitative differences, they all contain the 3 major antigens of the typhoid 
bacillus. The protection afforded by these vaccines  thus may be regarded  as 
supporting the concept  that, whether carried  in the laboratory or of clinical 
origin,  strains  which  possess  the  necessary  antigenic  composition  may  be 
utilized in the preparation of vaccines,  provided they are sufficiently stable. 
It does not appear,  therefore,  that the source and freshness of isolation of the 
culture are critical factors in the selection of vaccine strains. 
Since  1934, when Felix and Pitt  (39) first  associated  Vi antigen with the 
virulence of S. typhosa for mice, and the subsequent  demonstration (40) that 
this antigen or Vi antibody would protect these  animals  against a  virulent 
challenge, it has been generally accepted  that the presence of this component 
in typhoid vaccines was desirable.  This opinion has received further support 
from the reports of Findlay (41) and Felix and Anderson (42), which indicated 
that the mouse virulence  and Vi antigen content of organisms isolated  from 
human cases of typhoid fever were directly related to the severity of the disease. 
Consequently,  considerable emphasis has been given to selecting Vi-containing 
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vaccine preparation  which would result in maximal retention of this antigen 
(21, 43, 44). 
The present study has shown that the resistance of chimpanzees to infection 
with typhoid bacilli was significantly  increased by the administration  of Vi- 
containing whole organism vaccines, regardless of their manner d  preparation. 
The  protection  provided  by  the  heat-killed,  phenol-preserved  vaccine  was 
essentially the same as that afforded by the acetone-killed product, although 
the latter type of vaccine presumably contains a greater quantity of Vi antigen 
(21). Whether similar  vaccines prepared from non-Vi variants of these strains 
would protect under the same conditions remains for future work to determine. 
It is noteworthy, however, that in mice,  such non-Vi  vaccines are relatively 
ineffective in protecting against virulent challenge. 
The finding  that  vaccines of markedly different immunogenic  potency for 
mice  produced  apparently  equal  immunity  in  chimpanzees  is  of particular 
interest. It is pointed out that the chimpanzee experiments were not designed 
to establish quantitative  relationships  such as those developed in mice.  For 
the latter purpose, vaccines were administered in single, graded quantities to 
determine  the  minimal  immunogenic  dose.  In  contrast,  chimpanzees  were 
given a series of 3 injections of vaccine and a booster, a quantity which might 
conceivably have  obscured any difference  in  the protection afforded by the 
two products. On the other hand, it may be that, despite the limited numbers 
of animals employed in these experiments, the results obtained represent the 
actual relative potencies of the AK and HP vaccines for chimpanzees.  If so, 
mouse tests for vaccine potency do not accurately reflect the efficacy of vaccine 
for primates. The relationship between vaccine potency for mice and primates, 
however, remains  to  be established. 
With  respect to individual  antigenic  components,  the protection provided 
chimpanzees by the isolated antigens was less than that induced by the whole 
vaccines. "vVhen Vi antigen alone was employed, fever and bacteriemia occurred, 
but  in  fewer animals  and  with  shorter  duration  than  in  the  unimmuulzed 
group.  On  the  other  hand,  the  findings  in  the  animals  immunized  with  O 
antigen alone or with O antigen in combination with Vi were similar  to those 
seen in the controls, except that the group immunized with the Vi-O prepara- 
tion manifested a shorter period of bacteriemia and a smaller number of post- 
challenge  antibody increases.  It is noteworthy that Vi antigen alone did miti- 
gate the reaction of primates to oral challenge  with S. lypl~sa.  However, in 
assessing  the magnitude  of the protection induced  by this  purified antigen, 
it should be borne in mind that  the vaccines and isolated antigens were not 
compared  in  the  same  experiment.  Since  the  responses of the  chimpanzees 
varied  appreciably from one experiment  to  another,  and  the challenges  un- 
doubtedly fluctuated from one test to another despite uniform handling  and 340  IN~ECTION  AND  _n~gUNITY  IN  TYPHOID  FEVER.  HI 
standardization, it  would be  premature  to  draw  final conclusions regarding 
the  comparative  performance  of  whole  vaccines  versus  purified  antigens. 
Clearly, the findings with isolated Vi antigen justify further study so as  to 
evaluate more accurately the effectiveness of this antigen in immunization of 
man against typhoid fever. 
SUmmARY 
A study was made of the efficacy of various antityphoid immunizing agents 
in immunizing chimpanzees against typhoid fever produced by feeding viable 
S. typhosa. 
It  was  found  that  both  acetone-killed  and  heat-killed,  phenol-preserved 
typhoid vaccines were effective in protecting against infection induced with 
either homologous or heterologous strains of typhoid bacilli. 
Purified O  antigen induced no discernible protection, but some immunity 
was afforded by the administration of purified Vi antigen. 
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